Category Press Releases

RestorixHealth Marks Hyperbaric Awareness Month with Nationwide Celebration

RestorixHealth Marks Hyperbaric Awareness Month with Nationwide Celebration RestorixHealth, a leading provider of wound care and hyperbaric center management services across the United States, has announced its participation in recognizing Hyperbaric Awareness Month this May. The annual observance, launched in…

Read MoreRestorixHealth Marks Hyperbaric Awareness Month with Nationwide Celebration

Triton Robotic Endoscopy Achieves 100% Cecal Intubation with No Adverse Events in First-in-Human Study

First-in-Human Study of 50 Patients Shows Neptune Medical’s Triton Robotic Endoscopy System Achieves Zero Adverse Events and 100% Cecal Intubation in Colonoscopy Neptune Medical has reported encouraging results from its first-in-human clinical evaluation of the Triton Robotic Endoscopy System, marking…

Read MoreTriton Robotic Endoscopy Achieves 100% Cecal Intubation with No Adverse Events in First-in-Human Study

Alnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting Consistent Clinical Profile of Vutrisiran in ATTR-CM

Alnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting the Consistent Clinical Profile of Vutrisiran in ATTR-CM Alnylam Pharmaceuticals (Nasdaq: ALNY) has announced that it will present a comprehensive set of new data analyses for vutrisiran in patients…

Read MoreAlnylam Pharmaceuticals to Showcase New Analyses at Heart Failure 2026 Highlighting Consistent Clinical Profile of Vutrisiran in ATTR-CM

Rejoni Names MedTech Veteran John Nealon as Chief Executive Officer to Lead Women’s Health Innovation

Rejoni Names John Nealon as Chief Executive Officer to Lead Its Women’s Health MedTech Strategy Rejoni Inc., a privately held clinical-stage biotechnology company focused on advancing uterine health through innovative biomaterial therapies, has announced the appointment of John Nealon as…

Read MoreRejoni Names MedTech Veteran John Nealon as Chief Executive Officer to Lead Women’s Health Innovation

Ironwood Survey at DDW 2026 Highlights Need for Better Therapies to Reduce TPN Burden in SBS

Ironwood Presents Survey Data at DDW 2026 Highlighting Urgent Need for Treatments Addressing the Multifaceted Burden of Total Parenteral Nutrition in Short Bowel Syndrome Ironwood Pharmaceuticals, a biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare…

Read MoreIronwood Survey at DDW 2026 Highlights Need for Better Therapies to Reduce TPN Burden in SBS

Incyte Wins FDA Approval for Jakafi XR™ Extended-Release Tablets Across Multiple Hematologic Indications

Incyte Secures FDA Approval for Jakafi XR™ (ruxolitinib) Extended-Release Tablets Across Multiple Hematologic Indications Incyte has announced that the U.S. Food and Drug Administration (FDA) has approved Jakafi XR™ (ruxolitinib) extended-release tablets, introducing a new once-daily treatment option for patients…

Read MoreIncyte Wins FDA Approval for Jakafi XR™ Extended-Release Tablets Across Multiple Hematologic Indications

E-Scopics Secures FDA Clearance for Enhanced Hepatoscope®, to Be Showcased at DDW 2026

E-Scopics Secures FDA Clearance for Enhanced Hepatoscope® Featuring Advanced Elastography and Expanded Liver Disease Management Capabilities, to Be Showcased at DDW 2026 E-Scopics has announced a major advancement in its point-of-care ultrasound technology with new U.S. regulatory clearance for enhanced…

Read MoreE-Scopics Secures FDA Clearance for Enhanced Hepatoscope®, to Be Showcased at DDW 2026

Arrowhead Secures Australia TGA Approval for REDEMPLO® (plozasiran) in FCS

Arrowhead Pharmaceuticals Secures TGA Approval for REDEMPLO® (plozasiran) in Australia, Broadening Access for Patients with Familial Chylomicronemia Syndrome (FCS) Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) has announced a significant regulatory milestone with the approval of REDEMPLO by Australia’s Therapeutic Goods Administration…

Read MoreArrowhead Secures Australia TGA Approval for REDEMPLO® (plozasiran) in FCS
Acadia

Acadia Pharmaceuticals Announces Year-End Retirement of R&D Head Elizabeth H.Z. Thompson, Ph.D.

Acadia Pharmaceuticals Plans Year-End Retirement of R&D Chief Elizabeth H.Z. Thompson After Distinguished Career Acadia Pharmaceuticals Inc. has announced that Elizabeth H.Z. Thompson, Ph.D., its Head of Research and Development, plans to retire from her role for personal reasons. The…

Read MoreAcadia Pharmaceuticals Announces Year-End Retirement of R&D Head Elizabeth H.Z. Thompson, Ph.D.

Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Set to Enter CAR-T Market with 67% Complete Response Rate

Curocell’s RIMQARTO Injection Secures Full Regulatory Approval, Positioned to Enter CAR-T Market with 67% Complete Response Rate South Korean biotechnology company Curocell (KOSDAQ: 372320) has achieved a landmark milestone in the nation’s advanced therapeutics landscape with the full regulatory approval…

Read MoreCurocell’s RIMQARTO Injection Secures Full Regulatory Approval, Set to Enter CAR-T Market with 67% Complete Response Rate